VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 22, 2016) - THC BioMed Intl. Ltd. (CSE:THC)(OTC PINK:THCBF)(FRANKFURT:TFHC) is pleased to announce that our wholly-owned subsidiary, THC BioMed Ltd. has been granted a license to produce medical marihuana under Health Canada's Marihuana for Medical Purposes Regulations (MMPR).

Trading of THC.CSE was halted for one day this past Friday at the request of the company pending this announcement. Trading will resume as markets open on Monday, February 22.

"We are filled with emotion and pride and take this opportunity to thank our dedicated shareholders for helping us get to this point. Now we look forward to providing the highest quality product to our customers and value to our shareholders as we work diligently to build a world class cannabis company," said John Miller, President and CEO, THC BioMed Intl Inc.

THC BioMed has been granted authority to cultivate marihuana and the authority to conduct research and development with medical marihuana. Finalization of our application to produce cannabis oil is pending.

"As an investor and Director of THC BioMed Intl. Ltd. I want to thank the staff for reaching this important milestone. We have a unique approach to this business as evidenced by our focus on research and development as well as our agreement to acquire Supra; a Health Canada licensed Cannabis Testing Laboratory," commented George Smitherman.

THC's vision is to be on the leading edge of scientific research and development of products and services related to the medical cannabis industry. Management feels that THC is well positioned to be in the forefront of this rapidly growing industry where our high standard of excellence and our commitment to scientific research and new product and service development.

Please visit our website for a more detailed description of our business and services available:

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC. Forward-looking information is based on certain key expectations and assumptions made by the management of THC. Although THC believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Contact Information:

THC BioMed Intl. Ltd.
President and CEO
John Miller
604 682 1643